Very positive results in their drug in an experiment on Korna patients at Hadassah Ein Kerem Israel Hospital
Opinion only
No professional advice
Comment:
From Zion Shall Come Medication
The company is developing the drug Allocetra in collaboration with Hadassah Ein Kerem Hospital, which is designed to treat severe corona patients: 3 serious patients and 2 critical patients were released after about five days of administering the drug.
Patients fully recovered from the previous condition and were discharged from the hospital after an average of 5.5 days (patients in critical condition) and 8.5 days (patients in critical condition) after starting treatment with Allocetra. All patients received a negative result on the COVID 19 test at the time of discharge. No serious side effects were reported with Allocetra treatment and were considered tolerable.
Treatments such as plasma-based antibodies are usually given to patients in moderate condition. Allocetra, if approved, could potentially cover the gap, and treat patients in a critical / critical condition.
A single drug takes 24 hours to produce.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
The company is developing the drug Allocetra in collaboration with Hadassah Ein Kerem Hospital, which is designed to treat severe corona patients: 3 serious patients and 2 critical patients were released after about five days of administering the drug.
Patients fully recovered from the previous condition and were discharged from the hospital after an average of 5.5 days (patients in critical condition) and 8.5 days (patients in critical condition) after starting treatment with Allocetra. All patients received a negative result on the COVID 19 test at the time of discharge. No serious side effects were reported with Allocetra treatment and were considered tolerable.
Treatments such as plasma-based antibodies are usually given to patients in moderate condition. Allocetra, if approved, could potentially cover the gap, and treat patients in a critical / critical condition.
A single drug takes 24 hours to produce.